anti depdc1b  (Bioss)

Journal: Cancer Cell International

Article Title: Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma

doi: 10.1186/s12935-025-03667-4

Figure Lengend Snippet: Validation of real-world cohort based on the classifier. A The expression levels of CDC7, ASPM, CENPE, KIF23 and DEPDC1B on qRT-PCR results. B By inputting the mRNA levels of the 5 model genes into the classifier, the real-world UCEC cohort was identified as two G2MC subtypes. Representative immunohistochemistry images of CDC7, ASPM, CENPE, KIF23, and DEPDC1B in the two G2MC subtypes, magnification 40x. C K-M survival analysis of two G2MC subtypes based on optimal cutoff value grouping. The ending events are PFS. D The proportion of progression after treatment in the two groups of G2MC subtypes. E Comparing the proportion of patients with pathological grades G1 to G3 in the two G2MC subtypes in the real-world cohort. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Article Snippet: Subsequently, the sections were first incubated with primary antibodies CDC7 (1:200, CUSABIO, China), ASPM (1:200, CUSABIO, China), CENPE (1:500, Sanying, China), KIF23 (1:200, CUSABIO, China), and DEPDC1B (1:200, CUSABIO, China) at 4 °C overnight, and then incubated with multimerized anti-rabbit IgG-HRP secondary antibodies at room temperature for 90 min.

Techniques: Biomarker Discovery, Expressing, Quantitative RT-PCR, Immunohistochemistry

Journal: Frontiers in Genetics

Article Title: Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma

doi: 10.3389/fgene.2021.681809

Figure Lengend Snippet: immunohistochemistry of DEPDC1B in various types of cancer (A) and LIHC tissues (B–E) using HPA072558 antibody. (A) Strong cytoplasmic positivity was displayed in several hepatocellular carcinomas and single cases of carcinoma and urothelial cancer. Several endometrial cancers and a few other cancer tissues showed moderate immunoreactivity. The remaining cancer tissues were weakly stained or negative. Tumor cells staining: high expression (B,C) and medium expression (D,E) ; (B) Patient id: 3,477, male, age 67; (C) : Patient id: 5,032, female, age 58; (D) Patient id: 3,196, male, age 65; (E) Patient id: 4,823, female, age 25. DEPDC1B was mainly stained in the cytoplasmic/membranous LIHC cells using HPA072558 antibody (Atlas Antibodies Sigma-Aldrich).

Article Snippet: As indicated in , the DEPDC1B protein was strongly expressed in liver cancer, compared with that in other cancers using HPA072558 antibody (Atlas Antibodies Sigma-Aldrich) ( ).

Techniques: Immunohistochemistry, Staining, Expressing